Does Testosterone Replacement Therapy Affect Sleep?

Testosterone replacement therapy affects sleep differently depending on why sleep is disrupted. In hypogonadal men without sleep apnea, a 12-month controlled study found TRT improved sleep disturbance. The largest TRT trial to date — 5,204 men — found TRT improved mood and energy but not sleep quality. In men with severe sleep apnea, TRT temporarily worsened oxygen desaturation at 7 weeks; the effect resolved by 18 weeks. TRT is not a general sleep strategy.

Men considering or already using testosterone replacement therapy frequently ask whether it will improve their sleep. TRT clinic marketing often implies it will. The controlled evidence tells a more nuanced story — one that depends on why the man’s sleep is disrupted, whether he has obstructive sleep apnea, and what his body composition looks like.

This article covers the trial evidence on TRT and sleep quality, the interaction between TRT and obstructive sleep apnea, the emerging evidence for addressing sleep apnea before starting TRT, and why the largest TRT trial found no sleep benefit. It does not cover the full landscape of hormonal sleep disruption — for the broader picture, see Hormonal Sleep Disruption in Men. TRT targets testosterone deficiency — one contributor to sleep disruption. Cortisol dysregulation, GABA deficiency, inflammatory cytokines, and circadian disruption each fragment sleep independently — and may persist regardless of testosterone status.

Does Testosterone Replacement Therapy Improve Sleep in Men with Low Testosterone?

In a 12-month controlled study of hypogonadal men screened to exclude sleep apnea, TRT improved sleep disturbance, sexual function, and quality-of-life scores compared to untreated controls. But the TRAVERSE trial — the largest TRT placebo-controlled trial ever conducted, with 5,204 hypogonadal men — found that TRT improved mood and energy without improving sleep quality. The distinction: Shigehara’s population had sleep disruption driven by testosterone deficiency itself; TRAVERSE enrolled a broader hypogonadal population with multiple contributors to sleep disruption.

The direct evidence for TRT improving sleep comes from Shigehara et al. (2018), a subanalysis of the EARTH trial. The study enrolled 100 hypogonadal men screened for sleep disturbance, of whom 48 were analyzed — 24 receiving TRT, 24 as untreated controls — over 12 months. Men with pre-existing obstructive sleep apnea were excluded, isolating the effect of testosterone correction on sleep that was not confounded by breathing disorders.

After 12 months, the TRT group showed statistically better outcomes than controls across multiple measures: sleep disturbance, erectile function (SHIM scores), urinary function (IPSS scores), and quality-of-life domains (SF-36). The control group did not show comparable improvement. The authors proposed sleep disturbance as a clinical sign of severe hypogonadism — when sleep disruption is a direct consequence of testosterone deficiency, correcting the deficiency helps.

The TRAVERSE trial (Bhasin et al., 2024) complicates that picture. This was the largest TRT placebo-controlled trial to date: 5,204 hypogonadal men assigned to testosterone gel or placebo. Sleep quality was among the outcomes measured with validated instruments. TRT produced modest but statistically detectable improvements in depressive burden and energy — but no improvement in sleep quality or cognition.

This is a null finding from a well-powered trial of 5,204 men — not an incidental observation.

These two studies frame the central question. In the Shigehara population — men with primary hypogonadism, no sleep apnea, and sleep disturbance as a dominant feature — TRT helped. In the broader TRAVERSE population — men with hypogonadism and multiple potential contributors to sleep disruption — correcting testosterone alone did not resolve sleep complaints. The implication is that TRT improves sleep when testosterone deficiency is the primary driver of the sleep problem. In many men with low testosterone, sleep disruption has additional causes that testosterone correction does not address.

Can Testosterone Replacement Therapy Worsen Sleep Apnea?

In the only placebo-controlled trial testing TRT in men with severe sleep apnea, testosterone worsened oxygen desaturation by 10.3 events per hour at 7 weeks — but the effect was no longer detectable by 18 weeks. A separate trial of high-dose testosterone in older men reduced total sleep time by approximately one hour and increased respiratory disturbance. The worsening appears to be time-limited and dose-dependent.

Hoyos et al. (2012) conducted an 18-week placebo-controlled trial in 67 obese men with severe obstructive sleep apnea. At week 7, testosterone therapy worsened the oxygen desaturation index (ODI) by a mean of 10.3 events per hour compared to placebo (95% CI 0.8-19.8; p = 0.03). Time spent with oxygen saturation below 90% increased by 6.1 percentage points (95% CI 1.5-10.6; p = 0.01).

By week 18, neither measurement showed a difference between groups. ODI: mean difference 4.5 events/hour (95% CI -5.4 to 14.4; p = 0.36). Nocturnal hypoxemia: 2.9% (95% CI -1.9 to 7.7; p = 0.23). The worsening was transient.

One detail matters for interpretation: the worsening at week 7 was independent of baseline testosterone levels. Men with lower pre-TRT testosterone were not more or less likely to experience the breathing disruption. This indicates a pharmacologic effect of exogenous androgen, not a correction of deficiency producing an unexpected side effect.

Correlation between Aging Males Symptoms score and work functioning impairment in men with late-onset hypogonadism — (a) AMS Score and WFun. This Shows the Correlation Between the Total AMS Score and the Total WFun Score. “r” Represents the Correlation Coefficient, and “p” Indicates the Significance Probability. (b) AMS Score and SHIM. This Shows the Correlation Between the Total AMS Score and the Total SHIM. AMS = Aging Males Symptoms; WFun = Work Functioning Impairment Scale; SHIM = Sexual Health Inventory for Men. Shirakawa, T., Ide, H., Ikehata, Y., et al. (2025). Impact of Symptoms of Late-Onset Hypogonadism as a Potential Driver of Presenteeism. *American Journal of Men’s Health*, 19(4), 15579883251343972. https://pubmed.ncbi.nlm.nih.gov/40626351/

Liu et al. (2003) examined high-dose testosterone in 17 healthy men over 60 in a placebo-controlled trial. High-dose testosterone reduced total sleep time by approximately one hour per night (p < 0.05), increased both total and non-REM respiratory disturbance indices by approximately 7 events per hour (p < 0.05), and increased hypoxemia duration by approximately 5 minutes per night (p < 0.05). Upper airway dimensions did not change -- suggesting the worsened breathing was driven by central or neuromuscular mechanisms rather than anatomic airway narrowing.

The first 7 weeks after TRT initiation are the risk window for men with existing obstructive sleep apnea. Monitoring breathing parameters during this period is recommended. The Hoyos data show the worsening resolves — it is not a permanent contraindication — but the Liu data show that high-dose TRT carries greater breathing risk than physiological dosing.

Can Addressing Sleep Apnea Raise Testosterone Without Testosterone Replacement Therapy?

A 2026 study found that 3 months of CPAP therapy increased testosterone levels in obese men with severe sleep apnea — and the improvement correlated with the reduction in oxygen desaturation events independent of any change in body weight. Restoring sleep continuity may partially reverse the testosterone suppression caused by sleep-disordered breathing, reducing or eliminating the need for exogenous testosterone.

Amodeo et al. (2026) combined a cross-sectional phase (204 men hospitalized for severe obesity) and a longitudinal phase (14 newly identified men followed for 3 months on CPAP). In the cross-sectional group, 62.3% had low testosterone — consistent with a high prevalence of hypogonadism in men with severe obesity and sleep apnea. In multivariate modeling, decompensated obstructive sleep apnea was independently associated with lower testosterone (p = 0.014), alongside BMI (p = 0.039), type 2 diabetes (p = 0.006), and C-reactive protein (p = 0.003).

After 3 months of CPAP therapy, testosterone levels increased (p = 0.009). The oxygen desaturation index correlated with the magnitude of hormonal improvement independent of BMI changes (p = 0.04). In this 14-person longitudinal arm, the correlation suggests that reducing intermittent hypoxia and sleep fragmentation — rather than weight loss alone — contributed to testosterone recovery, though larger studies are needed to confirm the effect size.

Testosterone values before and after 3 months of CPAP therapy — Testosterone values before and after 3 months of continuous positive airway pressure (CPAP) therapy. T, testosterone. Amodeo, A., Cangiano, B., Del Duca, N., et al. (2026). The Role of Obstructive Sleep Apnea and CPAP Therapy in the Functional Hypogonadism of Male Patients With Severe Obesity. *The Journal of Clinical Endocrinology and Metabolism*, 111(5), 1272-1277. https://pubmed.ncbi.nlm.nih.gov/41284733/

Barrett-Connor et al. (2008) provided the population-level context for why this matters. In 1,312 older men, the association between low testosterone and poor sleep was attenuated after adjusting for BMI. Adiposity is a shared driver — men whose low testosterone is secondary to obesity and obstructive sleep apnea may restore testosterone through weight loss and CPAP without exogenous hormones.

The evidence-based sequence is: address obstructive sleep apnea first (CPAP, weight management), reassess testosterone after sleep is restored, and consider TRT only if testosterone remains low after the sleep disorder has been managed. Many TRT clinics begin testosterone before addressing sleep apnea — the Amodeo and Barrett-Connor data suggest that order should be reversed.

Why Doesn’t Testosterone Replacement Therapy Improve Sleep for Every Man?

Sleep disruption in men with low testosterone is rarely caused by testosterone deficiency alone. The TRAVERSE trial’s null finding on sleep — despite improvements in mood and energy — indicates that other contributors to sleep disruption persist after testosterone is corrected. Insomnia, sleep apnea, and circadian rhythm disruption are each independently associated with testosterone deficiency, and each has its own mechanism that TRT does not address.

The TRAVERSE result deserves closer examination. TRT improved energy and depressive burden, but not sleep quality. This dissociation suggests testosterone acts on wakefulness-related pathways — daytime vitality, motivation — rather than on the sleep-regulatory mechanisms of GABA tone, melatonin timing, and cortisol patterning that govern sleep onset and maintenance.

Agrawal et al. (2024) quantified the scope of the problem using a large U.S. claims database of men aged 40-70. After propensity score matching for age, hypertension, hyperlipidemia, diabetes, heart disease, tobacco use, and obesity, each category of sleep disorder was independently associated with testosterone deficiency at different strengths: circadian rhythm disruption carried an odds ratio of 2.63 (95% CI 2.54-2.73), insomnia carried an odds ratio of 1.74 (95% CI 1.73-1.76), and sleep apnea carried an odds ratio of 1.66 (95% CI 1.65-1.67).

The gradient matters. Circadian rhythm disruption — misalignment of sleep timing relative to the light-dark cycle — had the strongest association with testosterone deficiency, followed by insomnia, then sleep apnea. Correcting testosterone through TRT does not reset circadian timing, does not address the neurotransmitter changes that maintain insomnia, and does not resolve the upper-airway collapse that drives apnea.

Andersen and Tufik (2008) mapped the bidirectional mechanisms in a review of the testosterone-sleep literature. Testosterone release is tied to REM sleep — peak levels coincide with REM onset, and the nocturnal surge is sleep-dependent rather than purely circadian. Age-related reductions in REM sleep episodes correlate with lower testosterone concentrations. But REM sleep regulation itself depends on cholinergic tone, GABAergic activity, cortisol patterning, and circadian phase — none of which respond to testosterone correction. Testosterone deficiency is one variable alongside cortisol dysregulation, GABA decline, and circadian misalignment — each of which independently disrupts sleep and requires its own approach.

This is why the multi-cause framework matters for sleep disruption in men. A man with low testosterone, elevated cortisol, and reduced GABA tone is unlikely to restore sleep continuity with TRT alone. Each contributor needs to be identified and addressed according to its own mechanism. For the cortisol-testosterone interaction in nocturnal awakenings, see Can a Cortisol Spike Wake You Up at 3am?. For the role of GABA in sleep maintenance, see Can Low GABA Cause Waking Up at 3am?.

Testosterone replacement therapy addresses testosterone deficiency — one contributor to sleep disruption — but multiple causes often overlap. Cortisol dysregulation, GABA deficiency, inflammatory cytokines, and circadian disruption can each independently fragment sleep — and each may persist regardless of testosterone status. Identifying which causes might be involved is a useful next step.

Find out which causes might be driving your 3am wakeups →

Frequently Asked Questions

How Long Does It Take for Testosterone Replacement Therapy to Affect Sleep?

Sleep effects from TRT emerge over months, not weeks. The 12-month controlled study by Shigehara et al. showed gradual improvement across multiple sleep and quality-of-life measures. In men with sleep apnea, the initial worsening at 7 weeks resolved by 18 weeks. The TRAVERSE trial found no sleep improvement even at its endpoint. Men expecting immediate sleep improvement from TRT are likely to be disappointed.

The timelines across the available trials point in three different directions. Shigehara et al. (2018) measured outcomes at 12 months and found improvement — but their population had sleep disruption driven by testosterone deficiency with no competing causes. Hoyos et al. (2012) documented worsening at 7 weeks that resolved by 18 weeks — a transient pharmacologic effect on breathing, not a lasting change. The TRAVERSE trial (Bhasin et al., 2024) found no sleep improvement at any timepoint in a broader hypogonadal population.

The practical implication: if sleep does not improve within 3-6 months of TRT, the sleep disruption is likely driven by causes that testosterone correction does not reach — cortisol patterning, GABA tone, circadian misalignment, or unaddressed sleep apnea.

Should Men with Sleep Apnea Avoid Testosterone Replacement Therapy?

Current evidence does not support blanket avoidance of TRT in men with sleep apnea. The transient worsening documented by Hoyos et al. resolved by 18 weeks, and the 2026 evidence from Amodeo et al. shows CPAP can improve testosterone independently. The evidence-based approach is: address obstructive sleep apnea first, reassess testosterone after sleep is restored, and monitor breathing closely in the early weeks if TRT is initiated.

The Hoyos trial provides the most directly relevant data here. The worsening at week 7 was real — 10.3 additional oxygen desaturation events per hour — but it resolved by week 18 without changing the TRT regimen. This suggests the respiratory effect of exogenous testosterone is transient, not cumulative (Hoyos et al., 2012).

The Amodeo et al. (2026) data add an important option: 3 months of CPAP raised testosterone in obese men with severe sleep apnea, with improvement correlated to oxygen desaturation reduction rather than weight change. For men with both conditions, restoring breathing during sleep may partially resolve the testosterone deficiency, reducing or eliminating the need for TRT.

Can Improving Sleep Raise Testosterone Without Testosterone Replacement Therapy?

Sleep deprivation suppresses testosterone production. NHANES data show that sleep duration is associated with testosterone levels in age-dependent patterns, and the CPAP evidence demonstrates that restoring sleep continuity in men with obstructive sleep apnea partially restores testosterone without exogenous hormones. Improving sleep quality and duration is a first step that may reduce or eliminate the need for TRT in some men.

Hernandez-Perez et al. (2024) analyzed NHANES data from 8,748 adults and found the sleep-testosterone relationship follows different patterns by age. In young men aged 20-40, short sleep (6 hours or fewer) was associated with elevated testosterone (OR 3.62; 95% CI 1.37-9.53) — likely reflecting compensatory stress-axis activation. In middle-aged men aged 41-64, extended sleep (9 hours or more) was associated with low testosterone (OR 2.03; 95% CI 1.10-3.73), which may reflect hypersomnia as a marker of underlying hormonal decline.

The CPAP data from Amodeo et al. (2026) provide direct evidence that restoring sleep quality raises testosterone. The improvement correlated with the reduction in oxygen desaturation events independent of weight change (p = 0.04).

For men whose low testosterone co-occurs with poor sleep — whether from apnea, circadian disruption, or other causes — addressing the sleep disruption is a reasonable first step before committing to long-term TRT. For more on the bidirectional relationship between testosterone and sleep, see Does Low Testosterone Cause Sleep Problems in Men?.

Does Poor Sleep Quality Make Late-Onset Hypogonadism Worse?

A 2025 study of men with late-onset hypogonadism found that poor sleep quality was an exacerbating factor in workplace productivity loss, alongside fatigue, diminished motivation, and reduced libido. Sleep disruption in late-onset hypogonadism has measurable functional and economic consequences that extend into occupational performance.

Shirakawa et al. (2025) enrolled 96 men aged 27-76 with late-onset hypogonadism and measured both hypogonadal burden (Aging Males’ Symptoms scale) and work functioning impairment. The correlation between AMS scores and work impairment was moderate to strong (r = 0.62, p < 0.001), and poor sleep quality was identified as an exacerbating factor alongside fatigue, diminished motivation, and reduced libido.

Sleep disruption in late-onset hypogonadism is not an incidental co-occurrence — it has measurable downstream effects on daily functioning and productivity. This reinforces the case for assessing and addressing sleep quality as part of managing testosterone decline in aging men.

Are All Sleep Problems in Men Linked to Low Testosterone?

Sleep apnea, insomnia, and circadian rhythm disruption are each independently associated with testosterone deficiency, but with different strengths. Circadian rhythm disruption carried the strongest association (OR 2.63), followed by insomnia (OR 1.74) and sleep apnea (OR 1.66). The gradient suggests that disruption of sleep timing may have a stronger relationship with testosterone than intermittent hypoxia or sleep fragmentation alone.

Agrawal et al. (2024) quantified these associations in men aged 40-70 after adjusting for age, hypertension, hyperlipidemia, diabetes, heart disease, tobacco use, and obesity. All three sleep disorder categories were independently associated with testosterone deficiency and the associations remained after propensity score matching — indicating the relationships are not explained by shared cardiometabolic risk factors.

The graded pattern — circadian disruption > insomnia > sleep apnea — suggests that the more profoundly sleep architecture is disrupted, the greater the effect on testosterone regulation. Circadian misalignment disrupts the timing of the nocturnal testosterone surge itself. Insomnia fragments slow-wave sleep, which is when testosterone synthesis occurs. Apnea causes micro-arousals and intermittent hypoxia. Each mechanism is distinct, and each requires a different approach.

Not all sleep problems in men are caused by low testosterone. But testosterone deficiency and sleep disruption frequently co-occur — and the co-occurrence has multiple distinct pathways. For the full picture of how hormonal changes affect sleep in men, see Hormonal Sleep Disruption in Men.

References

1. Shigehara, K., Konaka, H., Sugimoto, K., Nohara, T., Izumi, K., Kadono, Y., Namiki, M., & Mizokami, A. (2018). Sleep disturbance as a clinical sign for severe hypogonadism: efficacy of testosterone replacement therapy on sleep disturbance among hypogonadal men without obstructive sleep apnea. The Aging Male, 21(2), 99-105. https://pubmed.ncbi.nlm.nih.gov/28920756/

2. Hoyos, C. M., Killick, R., Yee, B. J., Grunstein, R. R., & Liu, P. Y. (2012). Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clinical Endocrinology, 77(4), 599-607. https://pubmed.ncbi.nlm.nih.gov/22512435/

3. Liu, P. Y., Yee, B., Wishart, S. M., Jimenez, M., Jung, D. G., Grunstein, R. R., & Handelsman, D. J. (2003). The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. The Journal of Clinical Endocrinology and Metabolism, 88(8), 3605-3613. https://pubmed.ncbi.nlm.nih.gov/12915643/

4. Barrett-Connor, E., Dam, T.-T., Stone, K., Harrison, S. L., Redline, S., Orwoll, E., & Osteoporotic Fractures in Men Study Group. (2008). The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. The Journal of Clinical Endocrinology and Metabolism, 93(7), 2602-2609. https://pubmed.ncbi.nlm.nih.gov/18413429/

5. Andersen, M. L., & Tufik, S. (2008). The effects of testosterone on sleep and sleep-disordered breathing in men: its bidirectional interaction with erectile function. Sleep Medicine Reviews, 12(5), 365-379. https://pubmed.ncbi.nlm.nih.gov/18519168/

6. Amodeo, A., Cangiano, B., Del Duca, N., Chila, A., Musolino, A., Garavaglia, I., Delle Donne, E., Casiraghi, A., Manzini, C., Vezzoli, V., Sola, D., Gentile, I., Palo, A., Goggi, G., Federici, S., Persani, L., Scacchi, M., & Bonomi, M. (2026). The Role of Obstructive Sleep Apnea and CPAP Therapy in the Functional Hypogonadism of Male Patients With Severe Obesity. The Journal of Clinical Endocrinology and Metabolism, 111(5), 1272-1277. https://pubmed.ncbi.nlm.nih.gov/41284733/

7. Bhasin, S., Seidman, S., Travison, T. G., Pencina, K. M., Lincoff, A. M., Nissen, S. E., Miller, M. G., Flevaris, P., Li, X., Wannemuehler, K. A., & Pope, H. G. (2024). Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. The Journal of Clinical Endocrinology and Metabolism, 109(7), 1814-1826. https://pubmed.ncbi.nlm.nih.gov/38205962/

8. Agrawal, P., Singh, S. M., Able, C., Kohn, T. P., & Herati, A. S. (2024). Sleep disorders are associated with testosterone deficiency and erectile dysfunction-a U.S. claims database analysis. International Journal of Impotence Research, 36(1), 78-82. https://pubmed.ncbi.nlm.nih.gov/36473958/

9. Hernandez-Perez, J. G., Taha, S., Torres-Sanchez, L. E., Villasante-Tezanos, A., Milani, S. A., Baillargeon, J., Canfield, S., & Lopez, D. S. (2024). Association of sleep duration and quality with serum testosterone concentrations among men and women: NHANES 2011-2016. Andrology, 12(3), 518-526. https://pubmed.ncbi.nlm.nih.gov/37452666/

10. Shirakawa, T., Ide, H., Ikehata, Y., Lu, Y., Kinouchi, R., Iwasa, T., Koga, K., Tateishi, S., Fujino, Y., Yasui, T., & Horie, S. (2025). Impact of Symptoms of Late-Onset Hypogonadism as a Potential Driver of Presenteeism. American Journal of Men’s Health, 19(4), 15579883251343972. https://pubmed.ncbi.nlm.nih.gov/40626351/

Written by Kat Fu, M.S., M.S. — Last reviewed: May 2026 — 10 references cited